A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM101-015 trial
Affiliation
St. George's University Hospitals NHS Foundation Trust, St. George's University of London, LondonIssue Date
2022
Metadata
Show full item recordCitation
Fusi A, Gupta A, Lorigan P, Smith PL, Bowles M. A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM101-015 trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302373.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.9554Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.9554Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.9554